Skin Cancer Resource Center
Featured Content

Genomic Testing Reveals Gene Mutated in Pediatric Melanoma

Comprehensive clinical genomic testing of an adolescent patient, including whole genome sequencing, helped researchers identify mutations in a single gene that drive the most common childhood melanoma. 

Read More

Identifying a Mechanism of Resistance to BRAF Inhibitors in Melanoma

Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to the commonly used drugs that target the BRAF protein and its signaling pathway.

Read More

New! BRAF/MEK Inhibitor Combination Improves Survival for Melanoma Patients

A pooled analysis of the COMBI-d and COMBI-v trials revealed a 5-year overall survival (OS) in 34 percent of patients treated with a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily), according to research recently published in the New England Journal of Medicine.

Read More

Loading